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Although early stage ovarian cancer can be eectively
treated with surgery and chemotherapy, the majority of
cases present with advanced disease, which remains
essentially incurable. Unfortunately, little is known about
the genes important for the development and progression of
this disease. In this study, the expression of 68
phosphatases was determined in immortalized ovarian
epithelial cells (IOSE) and compared to ovarian cancer cell
lines. CL100, a dual specificity phosphatase, displayed
10 – 25-fold higher expression in normal compared to
malignant ovarian cell lines. Immunohistochemical stain-
ing of normal ovaries and 68 ovarian cancer specimens
confirmed this dierential expression. Re-expression of
CL100 in ovarian cancer cells decreased adherent and non-
adherent cell growth and induced phenotypic changes
including loss of filopodia and lamellipodia with an
associated decrease in cell motility. Induced expression
of CL100 in ovarian cancer cells suppressed intraperito-
neal tumor growth in nude mice. These results show for the
first time that CL100 expression is altered in human
ovarian cancer, that CL100 expression changes cell
morphology and motility, and that it suppresses intraper-
itoneal growth of human ovarian epithelial cancer. These
data suggest that down-regulation of CL100 may play a
role in the progression of human ovarian cancer.
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Introduction
Epithelial ovarian cancer is the fifth leading cause of
cancer mortality in women in the United States. In
2001, there will be an estimated 23 400 new cases of
ovarian cancer which will result in approximately
13 900 deaths, making ovarian cancer second among
gynecologic cancers in incidence and the most lethal
of the gynecologic malignancies (Greenlee et al.,
2001). The five-year survival of patients diagnosed
with ovarian cancer is approximately 30% and has
not changed appreciably over the past 30 years despite
important advances in surgery, radiation and che-
motherapy (Devesa et al., 1995). This emphasizes the
need for new therapies based upon a greater under-
standing of the molecular mechanisms underlying
ovarian carcinoma. Recent eorts to characterize
genetic alterations in epithelial ovarian cancer have
revealed extensive cytogenetic and molecular altera-
tions in these tumors (Cliby et al., 1993; Dodson et
al., 1993). However, very little is known about the
basic molecular mechanisms that deregulate the
growth of the ovarian epithelium and lead to invasive
and metastatic behavior of these tumors. To design
rational treatments, the genes involved in the devel-
opment and progression of ovarian cancer must be
identified.
In eukaryotic cells, there is a balance between the
activity of protein tyrosine kinases (PTKs) and protein
tyrosine phosphatases (PTPs) for the control of
dierent physiologic processes such as growth, dier-
entiation, and motility (Tonks and Neel, 1996; Neel
and Tonks, 1997). Malignant transformation can
occur when this balance is disturbed, either by an
increased activity of PTKs or by a decreased activity
of PTPs (Tonks and Neel, 1996; Neel and Tonks,
1997). PTKs have been considered key molecules in
the phosphorylation of tyrosine residues in a variety
of proteins (Tonks and Neel, 1996), but in recent
years more attention is directed to the growing
number of PTPs. Although, genome sequencing data
predict the existence of approximately 500 human
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PTPs (Neel and Tonks, 1997), their physiological
relevance is not yet well understood. PTPs are
characterized by at least a catalytic domain containing
a unique ‘signature motif’ (Neel and Tonks, 1997),
and several families of PTPs have been described:
transmembrane receptor-like PTPs, non-receptor non-
transmembrane PTPs, dual-specificity phosphatases
(DSPs) and low molecular weight phosphatases. A
variety of biological functions have been assigned to
these PTPs, including a possible role as tumor
suppressor genes for some PTPs (Fischer et al.,
1991). In an attempt to evaluate a potential role of
protein tyrosine phosphatases (PTPs) in human
epithelial ovarian cancer, we determined the dier-
ential expression of 68 dierent PTPs by RT–PCR in
a panel of human ovarian cancer cell lines compared
to normal ovarian cell surface epithelium immortalized
with the SV-40 large-T antigen (Maines-Bandiera et
al., 1992). CL100, the human homolog of Mitogen-
Activated Protein Kinase Phosphatase 1 (MKP-1) is
downregulated in ovarian cancer versus normal
immortalized cell lines. This report characterizes the
role of CL100 in ovarian cancer.
Results
Differential expression of CL100 in IOSEs versus
malignant ovarian cell lines
By using specific pairs of primers for dierent
phosphatases, patterns of relative expression of 68
phosphatases were identified in IOSE cells (Maines-
Bandiera et al., 1992), and these results were compared
to the expression patterns found in tumor cell lines
(Table 1), as it was hypothesized that dierences in
phosphatase expression between IOSEs and cancer
cells might be important for the biology of ovarian
cancer.
CL100, a dual specificity phosphatase (DSP), was
analysed further because it had high expression in
IOSEs and very low expression in ovarian cancer cell
lines. Other DSPs including those belonging to the
same family of MAPK phosphatases (such as MKP-2
and MKP-3) were not dierentially expressed. The
expression of CL100 was quantitated in a panel of 16
human ovarian cell lines by Northern blot (Figure
1a). High expression of CL100 was observed in the
two IOSE cell lines. Twelve out of 14 tumor cell lines
(86%) showed less than 13% of CL100 expression
(average 7%) compared to the IOSE cell lines,
including no detectable expression in OVT2 cells.
Cell line A224 expressed a similar level of CL100 as
the IOSE cells while tumor cell line A364 expressed
40%. As immortalization with T-antigen could lead
to alterations in gene expression in normal ovarian
cells, we compared the expression of CL100 in low
passage normal human ovarian surface epithelium
(HOSE) cells to that in IOSE 80 and IOSE 120. High
CL100 expression was also found in HOSE cells
(Figure 1b).
Decreased CL100 expression in ovarian cancer specimens
compared to normal ovarian epithelium
To determine whether CL100 expression was decreased
in primary ovarian cancer, 68 surgically resected
primary epithelial ovarian carcinomas and 10 normal
ovaries were immunohistochemically stained utilizing a
polyclonal antibody specific for MKP-1 (Santa Cruz
Biotechnology). The A224 cell line served as a positive
control and demonstrated intense nuclear staining with
minimal cytoplasmic staining (Figure 2a,b). Nine out
of 10 normal ovaries scored positive for nuclear
staining of the surface epithelial layer (Figure 2c,d).
Thirty-five per cent of tumors retained CL100 expres-
sion (Figure 2e – h and Table 2) and the dierence
between normal and tumor samples was statistically
significant (P=0.001 by Fisher’s exact test). Further-
more, immunostaining of the ovarian carcinoma
samples demonstrated a progressive loss of CL100
expression from early to late stage disease (Figure
2e – h). Advanced tumors (stages III and IV) revealed
minimally detectable staining and the negative correla-
tion between CL100 expression and the pathological
stage was significant (stage I and II versus stages III
and IV; P50.001 chi-squared test). Since histologic
Table 1 Expression level of phosphatases in immortalized ovarian
epithelial cells
High Intermediate-High Intermediate-Low Low
LAR PTP-TD14 PTPc rOST-PTP
PTPa PTPk rBEM-2 PTPf
SHP-2 PTPZ PTPga PTPzS
PEZ SAP-1 PTPeC PTPzL
PTP-1Ba PTPsP1 PTPd rPTPsPS
PEST PTPm LCA HePTPase
PTPmeg2 PTPba PTPz SHP1
PTP-BASab PTPeM PTP-BR7 PTP-BAS3E
PTP-1B PTP-H1 PTP-1Bb STEP
MTMR1 PTP-D1 PTP-BAS4E Mptp-HSCF
MTMR2 TC-PTP PTP-BASc PTP-BAS2E
MTMR3 TC-PTPa BDP1 mIA-2b
VHR PTP-BASa PEP ICAAR
VH-3 PTPmeg01 PTP-BAS5E PDSP2
CL100a TC-PTPb PTP-BAS23E
Cdc25ba PTP-BASb IA2
HCa MTM1 MAPKP-4
PRL-CAAX2 MMAC1/PTEN PRL-CAAX3
PDSP4 MKP-X PDSPinh
KAP-1 mPDSP1
VH-5 PDSP6
PIR1 PDSP5
MKP-3 mPDSP3
MKP-2
Cdc 25a
Cdc25ca
HCb
PRL-CAAX1
STYXb
aIndicates the only phosphatases that were dierentially expressed in
normal versus cancer cell lines. The rest of phosphatases were not
dierentially expressed. A two tailed student t-test was carried out
with the average expression values obtained from the RT–PCR
analysis of two normal immortalized ovarian cell lines and three
ovarian cancer cell lines as described in (Devesa et al., 1995; Dodson
et al., 1993). The a indicates P40.05 (t-test, two tailed)
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subtypes demonstrated dierent staining rates, we
analysed the relationship between stage and staining
within histologic subgroup. The only subgroup that
had sucient numbers to analyse were serous tumors,
which demonstrated a statistically significant dierence
between early and late stage (P50.05 by Fisher exact
test). The degree of dierentiation did not correlate
with CL100 expression.
As CL100 is inducible by dierent types of oxidative
stress (Keyse and Emslie, 1992), the CL100 RNA
expression in several ovarian cancer cell lines was
evaluated under oxidative stress. Hydrogen peroxide
(Figure 3) can increase CL100 RNA levels up to 15-
fold within 2 h of treatment with these oxidants and
remained elevated for up to 6 h. Cell lines with low
baseline expression of CL100 (A2780 and UCI101)
(Figure 3) responded to oxidative stress, suggesting
that normal regulation of CL100 by oxidative stress
does occur in ovarian tumor cell lines. However, OVT2
cells which display an abnormal CL100 genomic
structure, also failed to exhibit CL100 inducibility by
oxidative stress (Figure 3).
Re-expression of CL100 in ovarian cancer cells decreases
anchorage dependent and independent growth
The biologic role of decreased expression of CL100 in
ovarian cancer was assessed by reexpressing it in two
ovarian cancer cell lines (A2780 and UCI101) posses-
sing low endogenous levels of CL100. In addition to
having low endogenous levels of CL100, these cell lines
were chosen because they are easy to transfect and
have a high growth rate. Individual clones with stable
expression of CL100 as well as control clones in A2780
and UCI101 cells (Figure 4a) were isolated. The clones
isolated from A2780 (AL3, AL8, AL18 and AL21) and
UCI101 (UL2, UL11, UL12, and UL13) had CL100
protein levels, which were lower than those of the
IOSEs (not shown). Analysis of the subcellular
localization of CL100 in some of these transfectants
revealed that the majority of the protein localized to
the nucleus (Figure 4b). To assess whether the CL100
construct used was enzymatically active, quantitation
of MAP kinase activities in two of the CL100
expressing clones (AL18 and AL21) as well as in two
matched vector control clones (AC1 and AC3)
randomly chosen was performed. Decreased ERK-2
and JNK-1 but not p38 kinase activities as compared
to control clones was observed (Figure 4c), proving
that indeed the construct used is active. Analysis of
cellular proliferation revealed that CL100 transfected
clones in A2780 and UCI101 cells had a slower growth
rate than control clones (Figure 4d). There were no
Figure 1 (a) Northern blot showing CL100 expression in
immortalized and malignant ovarian cell lines. 28S RNA is
shown as loading control. Cells were collected in exponential
growth from subconfluent cultures and were processed as
indicated in the Materials and methods section. (b) Western blot
using HOSE cells and IOSE cells (5 mg of total protein was
loaded). The same membrane was probed with an anti-tubulin
antibody, used as loading control
Figure 2 Expression of CL100 in ovarian tissues and tumors. (a)
Immunohistochemical staining of the ovarian cancer cell line
A224 (which displays high constitutive expression of CL100, see
Figure 1) with a rabbit polyclonal antibody against MKP-1.
Nuclear staining is evident. (b) The same cell line stained with an
IgG isotype matched control antibody. No nuclear staining can
be seen. (c) H and E staining of normal ovarian surface epithelial
cells. (d) Immunohistochemical staining of the same ovarian
surface epithelial layer for CL100. (e) H and E staining of an
early stage papillary serous ovarian adenocarcinoma. (f) Im-
munohistochemical staining of the same tumor (E) for CL100. (g)
H and E staining of an advanced stage papillary serous ovarian
adenocarcinoma. (h) Immunohistochemical staining of the same
tumor (G) for CL100
Oncogene
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morphological signs of apoptosis in the cells over-
expressing CL100. CL100 expressing cell lines also had
a decreased ability to form colonies in soft agar as
compared with the vector control cells (Figure 4e).
CL100 expression decreases lamellipodia, filopodia and
cellular motility
To analyse the biological eects of CL100 in more
detail and eliminate potential problems from clonal
variation, we generated three UCI101 clones with
conditional expression of CL100 (U8 and U28) using
an amphotrophic retrovirus (Watsuji et al., 1997)
expressing CL100 under the control of a tetracycline
regulated promoter (rtTA, tet on system). The addition
of doxycycline (1 mg/ml) to the culture medium
induced expression of CL100 after 48 h (20-fold
increased) (Figure 5a), producing CL100 expression
levels comparable to those found in IOSE cells. The
addition of the same concentration of doxycycline to a
control clone (U30) did not induce expression of
CL100 (Figure 5a).
Under induction with doxycycline, all three UCI101
clones demonstrated reversible phenotypic changes by
the third day. Cells with conditional expression of
CL100 were flattened, enlarged and rounded compared
with uninduced cells or with U30+ cells, which had a
spindle-like morphology (Figure 5b). Induced cells
formed tight clusters, whereas uninduced cells (and
control clone U30) demonstrated close contact with
each other only upon confluence. A more detailed
characterization utilizing scanning electron microscopy
(s.e.m.) revealed a loss of filopodia and lamellipodia at
the leading edge of U28+ cells but not U30+ (Figure
6a). This result was confirmed by staining for F-actin
fibers, which revealed that lamellipodia and filopodia
present in U287 are decreased after CL100 induction
(Figure 6b). Since the morphological changes induced
by CL100 involve structures that are known to be
important for cell movement, cellular motility was
assayed. U28+ were less motile than the U287 cells in
vitro while the motility of the U30 clone was not
significantly dierent either in the presence or in the
absence of doxycycline (Figure 6c, P=0.00008 student
t-test).
CL100 decreases cyclin D1 expression
Since cyclin D1 has been demonstrated to be important
in the progression of the cell cycle mediated by growth
factor-induced MAPK pathways, the eect of CL100
on the expression of cyclin D1 was determined.
Decreased cyclin D1 protein expression was observed
in U28 upon induction with doxycycline (Figure 7a).
Similar results were obtained with U8 (data not
shown). Cotransfection of CL100 and a luciferase
reporter under the control of a 1.7 Kb fragment of the
cyclin D1 promoter demonstrated decreased reporter
activity in UCI 101 and A2780 parental cell lines
(Figure 7b), showing that transient expression of
CL100 can regulate cyclin D1 transcriptional activity
in these cell lines. Further analysis using shorter cyclin
D1 promoter constructs with deletion mutants of single
known consensus binding sites for dierent transcrip-
tion factors revealed that the downregulation of the
cyclin D1 reporter activity mediated by CL100 maps to
an AP1 site present at 7947 bp (Figure 7c). The
decreased reporter activity induced by transfection of
CL100 is abolished by using a deletion mutant of this
AP1 site in the cyclin D1 promoter.
CL100 expression suppresses intraperitoneal tumor
growth in nude mice
To test the in vivo relevance of CL100 expression in
ovarian cancer cells, tumor formation in nude mice was
studied (Table 3). Two dierent cell lines with
Table 2 CL100 expression in primary ovarian specimens
Number of Positive staining
patients %
Histology
Normal 10 9/10 (90)
Cancers 50 21/50 (42)
Serous 24 6/24 (25)
Mucinous 6 5/6 (83.3)
Clear cell 8 7/8 (87.5)
Endometrioid 11 3/11 (27.2)
Others 1 0/1 (0)
Stage
I 23 14/23 (60.8)
II 9 6/9 (66.6)
III 18 1/18 (5.5)
Differentiation
G1 8 5/8 (62.5)
G2 6 3/6 (50)
G3 29 9/29 (31)
Figure 3 Induction of CL100 by hydrogen peroxide. Cells
(A2780, UCI 101 and OVT2) were treated for half an hour with
200 mM H2O2 and then collected at the indicated time points and
analysed by Northern blot for CL100 expression
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Figure 4 (a) Western blot of A2780 stable transfectants. (1) C1, (2) C3 and (3) C4. 1,2 and 3 are control A2780 clones stably
transfected with pcDNA3; (4) AL3 (5) AL8 (6) AL18 and (7) AL21. Four to seven are A2780 clones stably transfected with
pcDNA3-CL100. Western blot of UCI101 stable transfectants: (1) UC4 (2) UC5 (3) UC6. One to three are control UCI101 clones
stably transfected with pcDNA3; (4) UL2 (5) UL11 (6) UL12 (7) UL13. Four to seven are UCI101 clones stably transfected with
pcDNA3-CL100. b-tubulin is used as a loading control on the same membranes. (b) Subcellular localization of CL100 in AL21 and
C3 (A2780 stable transfectants) by immunofluorescence as described in the Materials and methods section. (c) ERK-2, JNK-1 and
p38 kinase activities of A2780 CL100 transfectants (AL18 and AL21) versus A2780 transfected with empty vector alone (C1 and
C3). The results are expressed as percentage of control, and were measured in fmol/min/mg of protein, and are the mean and s.d. of
three independent experiments. Comparison of the kinase activity in control clones to CL100 expressing clones demonstrated a
statistically signficant dierence for ERK and JNK (P50.05) but not p38. (d) Cell proliferation as measured by a MTT colorimetric
assay of A2780 control clones (C1, C3 and C4) and A2780 cells overexpressing CL100 (AL3, AL8, AL18 and AL21). Cell
proliferation as measured by MTT colorimetric assay of UCI101 control clones (UC4, UC5 and UC6) and UCI101 cells
overexpressing CL100 (UL2, UL11, UL12, and UL13) is also shown. Each time point is the mean and standard deviation of eight
values. At three days, CL100 transfected clones in A2780 and UCI101 cells had a slower growth rate than control clones (P50.05).
(e) Number of colonies formed in soft agar by A2780 and UCI101 stable transfectants. CL100 expressing cell lines had a decreased
ability to form colonies in soft agar compared with vector control cells (P50.05). Each graph shows the results of a representative
experiment out of three performed showing similar results. For each experiment each cell line was done in triplicate as described in
the Materials and methods section
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Figure 5 (a) Western blot of UCI101 inducible clones U8 and U28, in the absence (7) or presence (+) of doxycycline 1 mg/ml for
48 h. U30 represents a UCI101 clone that was infected with the same retrovirus but did not express CL100 upon induction with
doxycycline. b-tubulin was used as a loading control in the same membranes. (b) Phase contrast microscopy showing the phenotypic
changes induced by conditional expression of CL100 in U28 (magnifications: 206 and 406) and U30 (magnification: 206). Cells
were plated in 100 mm dishes either in the presence (U28+ and U30+) or absence (U287 and U307) of doxycycline for 5 days
Figure 6 (a) Scanning electron microscopy showing the phenotypic changes induced by the conditional expression of CL100 in
U28 but not in U30. (b) Staining of F-actin fiber in U287 and U28+ cells (636 magnification). DAPI and F-actin fibers staining
was performed as described in Materials and methods. Arrows point to filopodia in U287 cells. (c) Motility of inducible clone U28
as compared to control clone U30. U28+ were significantly less motile than the U287 cells (P=0.00008); whereas, the U30 clone
was not significantly dierent in the presence or absence of doxycycline. The experiment was carried out as described in the
Materials and methods section. This figure shows one representative experiment (done in duplicate) out of three performed,
obtaining similar results
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conditional expression of CL100 were used: U28
(described above) and M18, which was obtained after
selection of A2780 ovarian carcinoma cells infected
with the pLRT-CL100 retrovirus. Since ovarian cancer
is primarily an intraperitoneal disease, sets of animals
were injected intraperitoneally as well as the more
standard subcutaneous location. Two independent
experiments were carried out. The first experiment
included 10 mice per cell line for the subcutaneous
location, and five per cell line for the intraperitoneal
location. Subcutaneous tumors were not significantly
dierent in any of the other cell lines used (U287 and
+ and M187 and +). However, the size of the
peritoneal tumors was suppressed in the cells with
conditional expression of CL100 (U28+ and M18+)
in comparison with the uninduced controls (U287 and
M187 respectively). This suppression reached statis-
tical significance in M18 cells (P=0.007, t-test) and a
clear trend was also observed in U28+ cells although
it did not reach statistically significance (P=0.06, t-
test). This lack of statistical significance was considered
to be the result of having an insucient number of
mice for the U28 cell line. Therefore, a second
experiment was carried out with a larger number of
mice for the intraperitoneal location (Table 3). Two
goals were pursued: first, to test the reproducibility of
the intraperitoneal eects found in M18+, and
secondly because it was estimated that the new number
of mice used in the second experiment would be
sucient to achieve statistical significance in the U28+
cells. Again, in the second experiment, mice with
doxycycline pellets have smaller peritoneal tumors than
those with placebo pellets in both cell lines: M18
(P=0.000, t-test) and U28 (P=0.011, t-test), whereas
the subcutaneous tumors (included as a control) were
not statistically dierent in any of the cell lines. It was
also noteworthy that U287 mice presented ascites
more often than U28+ mice (P=0.008, Fisher exact
test), indicating a more aggressive behavior in U287
as compared to U28+. Immunohistochemical analysis
with a specific anti-MKP1 antibody of the tumors
removed from nude mice showed that expression of
CL100 was present at similar levels in both subcuta-
neous and intraperitoneal tumors formed by M18+
cells (Figure 8). Expression of CL100 was decreased
and it presented a heterogeneous pattern in subcuta-
neous versus intraperitoneal tumors formed by the
U28+ cells (Figure 8). Therefore, in M18 cells
expression of CL100 did not suppress subcutaneous
growth but in U28 a decreased expression of CL100 in
the subcutaneous tumors could account, at least
partially, for the lack of a growth inhibition in the
subcutaneous location in this cell line.
Discussion
The recent identification of phosphatases in the
regulation of important signaling pathways implicated
in cancer prompted us to characterize their specific
patterns of expression in IOSE cells in comparison with
ovarian cancer cell lines. Utilizing a semiquantitative
RT –PCR assay provided us with a unique approach
to broadly screen for the dierential expression of
phosphatases in ovarian specimens. This report pre-
sents a systematic screening to identify potentially
relevant phosphatases involved in ovarian cancer
biology. There is only one previous study analysing
phosphatases in human ovarian cancer cells transfected
with HER-2/neu (Wiener et al., 1996). We found that
Figure 7 (a) Western blot of U28 cells in the absence (U287) or
in the presence (U28+) of doxycycline for the indicated time
points using a cyclin D1 antibody (20 mg of protein per lane was
loaded). The same membranes were probed sequentially with an
anti b-tubulin antibody. (b) Luciferase reporter assays with a
71.7 Kb cyclin D1 promoter fragment as described in (Tetsu and
McCormick, 1999). The amount of reporter construct used was
1 mg along with dierent proportions of pcDNA3-CL100 and
10 ng of renilla as control of transfection eciency. One
representative experiment done in triplicate is shown out of three
performed in the parental ovarian cancer cell lines A2780 and
UCI 101 as well as in the inducible U28 after 5 days of induction
with doxycycline. A statistically significant decrease in reporter
activity compared to empty vector controls was seen in
A2780 cells transfected with CL100 1 : 8, UCI101 cells transfected
with CL100 1 : 2 and 1 : 4, and U28+ cells compared to U287
(P50.05). (c) Luciferase reporter assay with a 1.7 Kb, 0.9 Kb and
a TCF and an AP1 deletion mutants of the human cyclin D1
promoter in UCI101 ovarian cancer cells. Solid bars indicate
reporter values of vector alone transfected cells. Striped bars
indicate reporter values of promoter construct transfected cells.
Decreased reporter activity induced by the transfection of CL100
is abolished by using a deletion mutant of this AP1 site in the
cyclin D1 promoter (P50.05)
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CL100 displayed reduced expression in epithelial
ovarian cancers compared to IOSE and HOSE cells.
CL100 is the human homolog of MKP-1 and is a
nuclear DSP (Keyse and Emslie, 1992; Charles et al.,
1992; Brondello et al., 1995; Sun et al., 1993; Alessi et
al., 1993). DSPs dier from classical PTPs in their
ability to dephosphorylate not only tyrosine but also
serine/threonine residues in proteins. MKP-1 and
CL100 were originally identified as ERK specific
phosphatases, capable of dephosphorylating this
MAPK (Sun et al., 1993; Alessi et al., 1993). However,
in some mammalian cell lines the inactivation of this
MAPK is too fast to indicate an involvement of CL100
in this process, and other phosphatases appear to be
involved in the inactivation of MAPK (Alessi et al.,
1995; Wu et al., 1994). Recent work has also
implicated MKP-1 in the inactivation of the other
members of the MAPK family, namely JNK and p38
in dierent model systems (Gupta et al., 1996; Chu et
al., 1996).
While we documented a large dierential expression
of CL100 in ovarian cell lines, it was important to
ensure that these dierences did not simply reflect the
immortalization of normal ovarian epithelial cells or
were the result of the establishment of cancer cell lines.
We analysed a large number of primary ovarian tissues
(normal and malignant). High nuclear expression of
CL100 was detected in normal ovarian epithelial cells.
The expression of CL100 decreases from normal
ovarian epithelium to early stage cancers and essen-
tially disappears in advanced ovarian cancer. This
finding partially parallels the expression patterns found
in several other human cancers. In prostate, colon, and
bladder, while overepxression of CL100/MKP-1 was
observed in the early phases of carcinogenesis, there is
a steady decrease in expression of MKP-1 with
increasing stage of disease (Loda et al., 1996; Magi-
Galluzzi et al., 1997). In contrast, there were detectable
levels of MKP-1 observed in all stages of the breast
cancer (Loda et al., 1996). However, the normal
epithelial tissues examined did not express CL100
(Loda et al., 1996). Of further note, our immunostain-
ing detected CL100 localized primarily to the nucleus
while previous work analysing other human cancers
has described primarily cytoplasmic staining (Loda et
al., 1996). These dierences may reflect pathologic
dierences in subcellular localization of CL100 in
dierent tumors. It is unlikely that these dierences
in subcellular localization are the result of technical
artifacts in the immunostaining, as the primary anti-
body used is specific for CL100/MKP-1 (as shown by
the appropriate controls and also by Western blot) and
previous studies finding a dierent subcellular localiza-
tion have used the same antibodies and a similar
Table 3 CL100 suppresses intraperitoneal but not subcutaneous tumor growth
Subcutaneous (grams) Intraperitoneal (grams) (ascites)
Cell line Exp. 1 (n=10) Exp. 2 (n=5) Exp. 1 (n=5) Exp. 2 (n=9) Exp. 1 Exp. 2
U287 1.10+1.70 0.22+0.24 4.93+1.04 0.92+0.17 3/5 8/9
U28+ 1.60+1.08 0.70+0.90 2.80+1.90a 0.58+0.30a 0.5c 2/9c
M187 1.73+1.35 2.37+2.52 4.95+1.48 6.75+1.94 0/5 0/9
M18+ 2.00+1.50 1.73+1.63 1.87+1.17b 1.69+1.47b 0/5 0/9
Experiment 1: aP=0.06 (t-test); bP=0.007 (t-test); cP=0.08 (Fisher exact test). Experiment 2: aP=0.011 (t-test); bP=0.000 (t-test); cP=0.008
(Fisher exact test)
Figure 8 (A and B) IHC staining using a specific CL100
antibody of tumors formed in nude mice by the U28 cell line
(206 magnification). (A1) U287 subcutaneous tumor. (A2)
U28+ subcutaneous tumor. (B1) U287 intraperitoneal tumor.
(B2) U28+ intraperitoneal tumor. (C and D) IHC staining of
tumors formed in nude mice by the M18 inducible cell line (206
magnification). (C1) M187 subcutaneous tumor. (C2) M18+
subcutaneous tumor. (D1) M187 intraperitoneal tumor. (D2)
M18+ intraperitoneal tumor
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technique to the one used in this study (Loda et al.,
1996). Nevertheless, some cytoplasmic staining of
CL100 was also observed in a small percentage of
ovarian cancer specimens. The downregulation of
CL100 occurs predominantly as the tumor progresses
from localized to advanced disease. This progression
event corresponds with the important clinical transition
in ovarian cancer from an essentially curable to
incurable cancer (Ozols et al., 1997). The mechanism
by which CL100 expression decreases remains to be
determined. The induction of CL100 by hydrogen
peroxide in two low expressing ovarian cancer cell lines
suggests that the downregulation is a transcriptional
event.
Our results show a decreased malignant potential of
ovarian cancer cells expressing CL100. Cells with
conditional expression of CL100 acquired a reversible
loss of the transformed phenotype, with the acquisition
of a flattened morphology that is characterized by a
decreased motility. This report shows, for the first time,
that restoring the expression of CL100 in ovarian
cancer cells to the levels seen in normal ovarian cells
has an inhibitory eect on cellular motility and growth.
However, our in vivo data are most striking. Ovarian
cancer cells with conditional expression of CL100 form
fewer and smaller intraperitoneal tumors in nude mice.
This is particularly relevant for a tumor that spends the
majority of its life within the peritoneal cavity.
CL100 is a nuclear phosphatase whose known
targets include the MAP kinases JNK and ERK (Sun
et al., 1993; Alessi et al., 1993; Gupta et al., 1996; Chu
et al., 1996) and in our transfectants the activities of
these kinases were inhibited. Attenuation of signaling
through MAPK pathways would alter gene expression.
Expression of MKP-1 blocks the induction of DNA
synthesis in quiescent REF52 fibroblasts by the V12
oncogenic mutant form of ras which is mediated by
MAPK (Sun et al., 1994), and in fibroblasts MKP-1
also inhibits entry into S phase (Brondello et al., 1995;
Noguchi et al., 1993). We demonstrated the down-
regulation of cyclin D1 in CL100 expressing cells and
that this regulation occurs at the AP-1 site in the cyclin
D1 promoter, which is consistent with a decreased
MAPK activity. These findings suggest that the cyclin
D1 is likely involved in the growth eects induced by
overexpression of CL100 in ovarian cancer cells as the
changes in cyclin D1 expression correlate with the
decreased growth rate observed. The mechanisms by
which CL100 alters cellular morphology and motility
are less clear but could involve the alterations of
expression levels of proteins involved in those processes
through attenuation of MAPK signaling. Of interest,
treatment of the cell lines with PD98059 at 25 mM
resulted in growth inhibition similar to CL100
expression (data not shown). However, inhibition of
MEK-1/2/5 did not produce morphologic changes seen
in the CL100 expressing clones. This suggests that
ERK may aect cellular proliferation while JNK is
more involved in cell morphology.
These findings provide a new insight into the biology
of ovarian cancer. A model for ovarian cancer in which
expression of CL100 acts as an important control in
the acquisition of a full malignant and metastatic
potential is proposed. Normal ovarian epithelial cells
express high levels of CL100 perhaps as control to
proliferative signals originating from the unique
exposure of the cells to the peritoneal cavity. The
decreased levels of CL100 found in early stage ovarian
cancers may be sucient to allow normal ovarian
epithelial cells to proliferate in the initial stages of
tumor formation. However, the complete loss of
CL100 expression seen in advanced ovarian cancers
would contribute to the acquisition of full metastatic
potential.
Recent work from other laboratories has demon-
strated the importance of the MAPK pathways in
cancer cell growth and tumorigenesis (Hoshino et al.,
1999; Sebolt-Leopold et al., 1999). It is known that
many oncogenes can constitutively activate the MAPK
pathway and that this inappropriate activation can
lead to malignant transformation (Webb et al., 1998).
Furthermore, activated MAPK or increased levels of
MAPK expression have been found in a diverse array
of human tumors such as breast, colon, lung and
kidney cancers (Hoshino et al., 1999; Sebolt-Leopold et
al., 1999). These observations have been exploited to
create pharmacological inhibitors of this pathway,
which could be of interest in a clinical setting. A
recent report on a new specific inhibitor of MEK-1/2/5
(PD184352) has demonstrated that this approach is
indeed eective in suppressing the growth of colon
tumors in vivo (Sebolt-Leopold et al., 1999). In
agreement with this data, our study shows that a
decreased MAPK and JNK activity in ovarian cancer
cells overexpressing CL100 correlates with the anti-
proliferative eects of CL100 expression seen in these
cells. As the presence of CL100 attenuates signaling
through the MAPK pathways, all these observations
point to the fact that ovarian epithelial cancer is a
tumor that relies heavily on MAPK pathways and
recent evidence, in addition to this report, supports this
view (Hoshino et al., 1999; Sebolt-Leopold et al.,
1999). Further, it has recently been shown that ovarian
cancer presents frequent amplification of PIK3CA
along with increased phosphatidylinositol 3-kinase
(PI3K) activity (Shayesteh et al., 1999), suggesting a
role for PIK3CA as an oncogene in ovarian cancer. It
has also been demonstrated that activation of PI3K
can lead to an increased ERK and JNK activity
(Antonyak et al., 1998; Sajan et al., 1999). In ovarian
cancer the expression of CL100 could act as an
important control for increased MAPK signaling
resulting from activated upstream pathways. Loss of
CL100 expression would contribute to the transition
from local to advanced ovarian tumors by allowing
increased MAPK activation, and providing a unique
and novel regulatory mechanism that is not present in
other epithelial tumors.
In summary, our data strongly support the role of
CL100 as a regulatory mechanism in the progression of
ovarian carcinoma, and they shed new light in the
biology of epithelial ovarian cancer. These findings also
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open a new avenue for therapeutic intervention in these
tumors.
Materials and methods
Plasmids and retrovirus production
pcDNA3-CL100 was prepared by subcloning a 1.2 kb Sma I/
XhoI fragment from pMT2T-CL100 (a kind gift from K
Kelly, NCI, Bethesda, MD, USA) into the EcoRV/XhoI site
of pcDNA3 (Invitrogen).
Full length CL100 cDNA was cloned into a retroviral
vector (pLRT) containing the two components of the reverse
tetracycline-regulated (rtTA) system as described (Watsuji et
al., 1997). UCI101 and A2780 cells were infected with the
retrovirus pLRT-CL100 essentially as described (Watsuji et
al., 1997).
Cell culture and cell culture assays
IOSE (immortalized ovarian surface epithelium) 80 and IOSE
120 are low passage normal ovarian surface epithelial cells
which were immortalized with a SV40 large-T antigen-
containing vector as described previously (Maines-Bandiera
et al., 1992). These cells have an increased life span and
express characteristics of normal ovarian surface epithelium.
Given the diculty in obtaining human normal ovarian
surface epithelium, IOSE cells provide an in vitro model to
study the biology of this epithelium.
The source of the ovarian carcinoma cell lines used in this
study and the primary tumors they were derived from is as
follows: AD10, UCI 101, UCI 107, A2780, OVCAR3,
CaOv3, CP70, OVT2 A224, A364, A547 and SKOV3 were
derived from papillary serous adenocarcinomas; OVCAR429
was derived from a serous cystoadenocarcinoma, and 222 was
established from an endometriod adenocarcinoma. 222,
AD10, UCI 101, UCI 107, and SKOV3 was kindly provided
by Dr G Scott Rose, University of California, CA, USA;
A2780, OVCAR3 and CaOv3 were obtained from the ATCC;
cell line CP70 was provided by Dr Eddie Reed, NCI MD,
USA; OVT2 was established in our laboratory; OVCAR429
was kindly provided by Dr David Spriggs, Memorial Sloan
Kettering NY, USA; A224, A364, and A547 were provided
by Dr Jacques DeGreves, Brussels, Belgium. Ovarian cell
lines were cultured as described previously (Hendricks et al.,
1997).
Stable transfection of ovarian cancer cell lines A2780 and
UCI101 was carried out by electroporation using a Bio-Rad
(Hercules, CA, USA) electroporator. Cells were transfected
with either pcDNA3-CL100 or with pcDNA3 and selected
(without trypsinization) with G418 500 mg/ml for 2 – 3 weeks.
After selection, independent clones were isolated using
cloning cylinders.
For oxidative stress assays, 26106 cells were plated in
100 mm dishes and treated with 200 mM hydrogen peroxide
for 30 min. The cells were then collected at dierent time
points for the isolation of total RNA. Cellular proliferation
assays were performed using a MTT (dimethyl thiozolyl-2’,5’-
diphenyl-2-H-tetrazolium bromide) -based assay (Non radio-
active proliferation assay, Promega Corp., Madison, WI,
USA) as previously described (Sabichi et al., 1998).
Anchorage independent growth was done as previously
described (Sabichi et al., 1998). Colonies were scored with
an Omnicon 3600 image analysis system (Imaging Products
International, Inc. Chantilly, VA, USA) on day seven for
A2780 stably transfected clones and on day 12 for UCI101
clones.
RNA isolation and Northern blot analysis
Total RNA was prepared from subconfluent cells using the
standard guanidin isothiocyanate CsCl method. Ten micro-
grams RNA samples were electrophorised in 1% agarose gels
containing formaldehyde and were transferred to Nytran N+
membranes (Schleicher and Schuell, Keene, NH, USA).
Filters were incubated overnight with cDNA probes labeled
with P32-dCTP. The probes used were: a XhoI/EcoRI
fragment (from pMT2-CL100, see below) of the human
CL100 cDNA corresponding to part of the 3’ untranslated
region or the full length CL100 cDNA. After an overnight
hybridization at 608C, blots were washed and exposed to
XAR films (Kodak, Rochester, NY, USA). Signals were
quantitated using a densitometer (Molecular Dynamics,
Sunnyvale, CA, USA). To normalize for dierences in
RNA loading, all signals were adjusted based on the signal
from the corresponding 28S ribosomal RNA band as
visualized by ethidium bromide staining and UV illumina-
tion.
RT–PCR screening
RT–PCR was carried out using the conditions and primers
essentially as described in Dayton and Knobloch (Dayton
and Knobloch, 1997; Barnea et al., 1994). Specifically, for
reverse transcription total cellular RNA was extracted from
normal (IOSE 80, IOSE120) and malignant (AD10, CP70,
222) ovarian epithelial cell lines as described above.
Complementary DNAs were prepared by random hexamer-
primed reverse transcription (RT) of 0.5 mg of total RNA in
a 20 ml reaction volume. A mixture of the RNA and 50 pmol
random hexamers was heated to 758C for 5 min and was
rapidly cooled on ice. An RT master mix was then added
such that the final concentrations were 50 mM KCl, 10 mM
MgCl2, 20 mM Tris, 625 mM each of dATP, dCTP, dGTP,
TTP, 2.5 mM dithiothreitol, 0.5 units rRNAsin/ml (Promega)
and 2.5 units Superscript RT/ml (Gibco BRL). RT reactions
were incubated at room temperature (258C) for 15 min, at
428C for 15 min, and at 558C for 15 min. The RT was
inactivated at 758C for 15 min.
PCR amplification
A series of primers that correspond to specific PTPs were
synthesized based on human sequence data when available.
For those PTPs that had not been cloned from humans, the
original primer sequences were chosen from the cDNA for
the species of first cloning. Human primers were then based
on the human sequences from the amplicons generated using
the non-human primers. Primers were designed to yield
amplicons ranging in length from 171 to 566 bp with
temperatures for optimal PCR between 53.2 and 62.08C.
The characteristics of most of the PTPs primers used for
these studies have been previously described (Dayton and
Knobloch, 1997). The primer sets for the long and short
extracellular forms of the receptor-like PTPs PTPx, PTPxL
and PTPxS (Barnea et al., 1994) included a common
antisense primer (TTC TTG TGC TTG TTG TCT GGG
TG) and unique sense primers (GAA TGA GAC TTC CAC
AGA TTT CAG TTT and TGC CAC ATT ATT CTA CCT
TTG CCT AC respectively). Primers for 10 additional PTPs
and PTPs-like expressed sequence tags (ESTs – 6 putative
dual specificity phosphatases and a potential phosphatase
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inhibitor) (PTP-TD14, PIR1, PRLCAAX3, PDSP1, PDSP2,
PDSP3, PDSP4, PDSP5, PDSP6, and PDSPinh) will be
described elsewhere (MA Dayton, manuscript in prepara-
tion). RT –PCR was done with template dilution and four
sets of reactions with dierent annealing temperatures. The
RT mixture was diluted 10 – 1000-fold in water so that
amplicons of dierent abundance could be amplified in
parallel with the same number of cycles. Based on the
abundance of each amplicon in preliminary analysis, target
sequences within 1 ml of the appropriate dilution of the
cDNA reaction were amplified in 10 ml reactions containing
0.25 units of Taq, 2 pmol each of the sense and antisense
primers in PCR buer, 62.5 mM of each dNTP, and 0.05 ml
[a-P32]dCTP. Control PCR reactions using no added DNA
template and using no RT were done as sets after the cell line
cDNA amplifications were complete. All PCR reaction
components except for the primers and template were
prepared as a master mix, which was subsequently aliquoted
and overlaid with mineral oil. Both the master mix and the
oil were added to the back inside of the PCR tube. All
reactions were ‘hot-started’ as follows. One microliter each of
the appropriate cDNA dilution and of a primer pair solution
containing 2 pmols of each primer was deposited onto the
front inside of the PCR tube, where they remained because of
surface tension. The caps of the tubes were closed and then
were placed into the thermal cycler. After heating the
aliquoted master mixes to 808C, the primers and template
were mixed into the reaction solution. The samples were then
briefly spun in a microcentrifuge to re-establish the oil layer
on top. Amplification of each of the primer pair/template
reactions was performed in parallel using the same master
mix for each RT. Reactions were grouped into sets based on
the optimum temperature for amplification –Tamp from
53.5 – 55.48C were performed at 548C, 55.5 – 57.48C at 568C,
57.5 – 59.48C at 588C, and 59.5 – 62.08C at 608C. The first two
cycles of PCR consisted of denaturing at 978C for 45 s,
primer annealing at 548C, 568C, 588C or 608C for 300 s, and
primer extending at 728C for 60 s. An additional 28 cycles
were completed under identical conditions except that the
denaturation temperature was decreased to 948C and the
annealing time was decreased to 60 s.
Following electrophoresis through 1.5% Tris-Borate-
EDTA (TBE) agarose gels, the amplicons were transferred
by electroblotting to GeneScreen Plus nylon membranes
(Dupont, Boston, MA, USA). DNA was fixed to the
membranes by air-drying. The images were detected by
PhosphorImager on a Molecular Dynamics PhosphorImager
and were analysed by volume integration with the Image-
Quant software. The expression levels for each of the PTPs
were normalized to the G3PDH expression, taking into
account the various dilutions of the RT made prior to the
PCR.
Immunohistochemistry
Five micron formalin-fixed, paran-embedded tissue sections
were used for immunohistochemical staining with specific
rabbit polyclonal antibodies against MKP-1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at a dilution of 1 : 50
utilizing standard techniques (Birrer et al., 1999). Positive
controls of formalin-fixed paran-embedded sections in-
cluded human tissues known to express high levels of
CL100. The ovarian cancer cell line A224 with high
endogenous levels of CL100 also served as positive control.
Negative controls consisted of the incubation of serial
(positive) ovarian tumor sections with an unrelated rabbit
IgG polyclonal antibody. A previous immunohistochemical
study using the same primary antibodies (at the same 1 : 50
dilution) to evaluate the expression of CL100 in other human
tumors, also showed the specificity of the staining with these
antibodies (Loda et al., 1996). Antigen retrieval was not
performed in our study. In the previous study mentioned
above, antigen retrieval did not reveal nuclear localization of
CL100 in other human tumors (Loda et al., 1996). Staining
was initially scored by both percentage of nuclei stained and
intensity of the staining. Since the intensity of the staining
was found to be similar in all specimens only the percentage
of nuclei stained was reported. Results of the staining were
reviewed independently without knowledge of the clinical
data by two of the authors (RG Manzano and LM
Montuenga) who scored the percentage of positive nuclei
within tumors and in the normal ovarian surface epithelium.
A score of 25% or higher was considered positive. Formalin-
fixed, paran-embedded tissues were obtained from CHTN,
National Naval Medical Center and Walter Reed Army
Medical Center according to Institutional Review Boards
approved protocols.
Western blotting analysis and kinase assays
Specific polyclonal antibodies against MKP-1 or cyclin D1
(both from Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were used as primary antibodies. A specific antibody
against b-tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) was used as loading control on the same
membrane used to assay for the expression of CL100 or
cyclin D1. ERK-2, JNK-1 and p38 kinase activities were
measured as previously described with minor modifications
(Auer et al., 1998).
Immunofluorescence, F-Actin staining, and scanning
electron-microscopy
Cells that had been grown on sterile coverslips were fixed
with 3.7% formaldehyde in phosphate-buered saline (PBS)
for 10 min and then extracted with 0.2% Triton X-100 for
10 min at room temperature. After blocking nonspecific
binding sites, anti-MKP1 antibody (Santa Cruz) was added
to the coverslip and incubated for 1 h at 48C. After the
coverslip was washed, it was incubated at 48C with
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit
immunoglobulin (Molecular Probes). Finally, cells were
stained with 0.4 mg/ml of DAPI (Sigma) for 10 min at room
temperature. For actin staining, cells were processed as
described above. Following fixation and extraction, one unit
of rhodamine phalloidin (Molecular Probes) was added to the
coverslip as recommended by the manufacturer and in-
cubated at room temperature. Cells were stained with 0.4 mg/
ml of DAPI (Sigma) for 10 min at room temperature. Cells
were visualized on a Zeiss Axiovert microscope using a 636
objective, and images were captured with an Optronics CCD
camera.
For scanning electromicroscopy cells that had been grown
on sterile coverslips were fixed with glutaraldehyde. After
coating, cells were examined under scanning electron
microscope.
Cell motility assay
FALCON cell culture inserts with an 8 mm pore-size PET
membrane (Fisher Scientific) were coated with collagen 3 mg/
ml for 2 h at 378C, and placed into the wells of a 24-well
plate containing 0.5 ml of RPMI supplemented with 0.5%
serum and EGF at 10 nM. 350 ml of the cell suspension
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(0.756105 cells/ml in RPMI with 0.5% serum) was added to
each insert. The plate was incubated for 24 h at 378C and
then the inserts were removed. Cells that had migrated
through the insert and adhered to the bottom of the
membrane were stained and then counted. Six high power
fields randomly chosen were counted. The assay was
performed in duplicate and repeated three times.
Luciferase assays
These assays were done as described with minor modifica-
tions using renilla as control for transfection eciency (Tetsu
and McCormick, 1999). All assays were done in triplicate and
each experiment was repeated at least three times.
Nude mouse tumorigenicity
Nude mice were injected either subcutaneously or intraper-
itoneal with uninduced or induced (5 days) U28 or M18 cells.
By using the tetracycline inducible system each clone serves
as its own control to assure that the biologic eect seen is
from the induced gene and not the result of clonal variation.
A placebo or doxycycline pellet (Innovative Research of
America, Sarasota, Florida, USA) was implanted in each
mouse the day before the injection of the tumor cells. For the
subcutaneous injections, 107 cells were injected. All mice that
received the same cell line (whether induced or uninduced)
were sacrificed the same day, when one or more developed a
tumor volume of 2000 mm3 or more as measured with a
caliper. Tumors were removed and weighed. For the
peritoneal injection, 26107 cells were injected per mouse.
Mice were sacrificed the same day after a 3-week period for
M18 or after 6 weeks for U28. All macroscopic tumor was
removed and weighed.
Statistical methods
Statistical analysis of the staining results was done using the
w2 test and the Fisher exact test. Statistical analysis of the
motility and of the in vivo study results was carried out using
the student t-test (two tailed). The Fisher exact test was used
to compare the statistical significance of the number of
animals presenting ascites.
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